Published in Eur J Immunol on August 01, 2001
Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. Infect Immun (2005) 2.05
Use of tumour-responsive T cells as cancer treatment. Lancet (2009) 1.73
Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun (2006) 1.67
Toll-like receptor agonists in cancer therapy. Immunotherapy (2009) 1.58
TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene (2009) 1.52
The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats. Brain Res (2008) 1.45
TNF-alpha-mediated inflammation in cerebral aneurysms: a potential link to growth and rupture. Vasc Health Risk Manag (2008) 1.31
The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4. J Neurosci (2015) 1.24
Manifold mechanisms of Toll-like receptor-ligand recognition. J Clin Immunol (2005) 1.22
Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. J Pain (2014) 1.22
Chemoimmunotherapy. Cancer J (2010) 1.13
TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther (2013) 1.11
Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother (2013) 1.11
Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells. Immunol Lett (2008) 1.08
Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res (2014) 1.08
Polysaccharides from the root of Angelica sinensis promotes hematopoiesis and thrombopoiesis through the PI3K/AKT pathway. BMC Complement Altern Med (2010) 1.05
Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev (2013) 1.05
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol (2010) 1.01
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med (2010) 1.01
Mechanisms involved in the development of chemotherapy-induced neuropathy. Pain Manag (2015) 1.01
TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro. Oncol Lett (2013) 1.01
Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS One (2008) 0.99
Moxibustion inhibits interleukin-12 and tumor necrosis factor alpha and modulates intestinal flora in rat with ulcerative colitis. World J Gastroenterol (2012) 0.99
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol (2012) 0.98
Regulation of ultraviolet radiation induced cutaneous photoimmunosuppression by toll-like receptor-4. Arch Biochem Biophys (2011) 0.96
The Role of TLR4 in Chemotherapy-Driven Metastasis. Cancer Res (2015) 0.95
Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor alpha production. Mol Pharmacol (2008) 0.94
MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med (2006) 0.93
Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium. J Immunol (2009) 0.93
Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis. Mol Carcinog (2009) 0.92
Analysis of signal transduction pathways in macrophages using expression vectors with CMV promoters: a cautionary tale. Inflammation (2005) 0.92
Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides. J Med Chem (2012) 0.90
Toll-like receptor-4 deficiency enhances repair of UVR-induced cutaneous DNA damage by nucleotide excision repair mechanism. J Invest Dermatol (2013) 0.90
Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci (2008) 0.90
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med (2008) 0.90
Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammation. Genes Dis (2014) 0.90
Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesth Analg (2012) 0.89
Differential effects of Paclitaxel on dendritic cell function. BMC Immunol (2010) 0.88
The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol (2013) 0.86
Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells. J Transl Med (2012) 0.86
Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. J Pain (2016) 0.85
MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy. Brain Behav Immun (2015) 0.85
Mycobacterial PIMs inhibit host inflammatory responses through CD14-dependent and CD14-independent mechanisms. PLoS One (2011) 0.85
Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep (2014) 0.85
Selective activation of nuclear factor kappa B in the cochlea by sensory and inflammatory stress. Neuroscience (2009) 0.83
Cell mediated immune responses through TLR4 prevents DMBA-induced mammary carcinogenesis in mice. Int J Cancer (2011) 0.82
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int (2015) 0.82
The role of TLR4 in the paclitaxel effects on neuronal growth in vitro. PLoS One (2013) 0.81
Endotoxin-Binding Peptides Derived from Casein Glycomacropeptide Inhibit Lipopolysaccharide-Stimulated Inflammatory Responses via Blockade of NF-κB activation in macrophages. Nutrients (2015) 0.81
Over-expression of TLR4-CD14, pro-inflammatory cytokines, metabolic markers and NEFAs in obese non-diabetic Mexicans. J Inflamm (Lond) (2014) 0.81
Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance. Biomacromolecules (2015) 0.80
Paeonol Suppresses Neuroinflammatory Responses in LPS-Activated Microglia Cells. Inflammation (2016) 0.79
New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy. Asia Pac J Oncol Nurs (2016) 0.78
Effects of glycine on phagocytosis and secretion by Kupffer cells in vitro. World J Gastroenterol (2012) 0.77
Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Support Care Cancer (2015) 0.77
Adjuvant effect of docetaxel on the immune responses to influenza A H1N1 vaccine in mice. BMC Immunol (2012) 0.77
KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med (2009) 0.77
Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA. Nanomedicine (2015) 0.76
Paclitaxel effects on the proteome of HL-60 promyelocytic leukemic cells: comparison to peloruside A. Invest New Drugs (2010) 0.76
Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro. Toxicol In Vitro (2017) 0.75
Diversities of interaction of murine macrophages with three strains of Candida albicans represented by MyD88, CARD9 gene expressions and ROS, IL-10 and TNF-α secretion. Int J Clin Exp Med (2014) 0.75
Paclitaxel inhibits the hyper-activation of spleen cells by lipopolysaccharide and induces cell death. J Vet Sci (2016) 0.75
Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4. PLoS One (2017) 0.75
Macrophage Polarization Contributes to the Anti-Tumoral Efficacy of Mesoporous Nanovectors Loaded with Albumin-Bound Paclitaxel. Front Immunol (2017) 0.75
Docetaxel inhibits bone resorption through suppression of osteoclast formation and function in different manners. J Bone Miner Metab (2008) 0.75
Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One (2017) 0.75
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 18.80
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 17.40
Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 16.86
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 14.24
Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity (1999) 11.64
Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J (1998) 9.36
TLR signaling. Cell Death Differ (2006) 9.24
Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science (1992) 9.01
Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity (1999) 7.90
Toll-like receptors control activation of adaptive immune responses. Nat Immunol (2001) 7.54
Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med (1997) 7.12
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol (2000) 6.61
Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56
Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 6.02
Deactivation of macrophages by transforming growth factor-beta. Nature (1988) 5.56
Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol (2001) 5.36
ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep (2001) 5.32
Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol (2001) 5.27
Biological and clinical aspects of interleukin 6. Immunol Today (1990) 5.17
Cytokine signal transduction. Cell (1994) 5.14
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A (2001) 5.02
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70
Interleukin-6 family of cytokines and gp130. Blood (1995) 4.52
Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J (1997) 4.51
Induction of direct antimicrobial activity through mammalian toll-like receptors. Science (2001) 4.46
Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem (1999) 4.38
Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell (1995) 4.34
Endovascular stent-graft placement for the treatment of acute aortic dissection. N Engl J Med (1999) 4.33
Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1993) 4.23
Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol (2000) 4.10
IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1989) 4.03
ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell (1998) 3.98
Limb and skin abnormalities in mice lacking IKKalpha. Science (1999) 3.85
Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A (1993) 3.59
IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol (1998) 3.56
Interleukin-6 and its receptor: a paradigm for cytokines. Science (1992) 3.51
Pig cloning by microinjection of fetal fibroblast nuclei. Science (2000) 3.51
Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci U S A (2001) 3.49
Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J (1991) 3.41
Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell (1999) 3.27
Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol (2001) 3.26
Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J (1999) 3.19
Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol (2000) 3.10
CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med (2001) 3.05
Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev (1999) 2.91
IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol (1999) 2.84
Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity (2000) 2.81
Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell (1997) 2.64
STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A (1996) 2.64
Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin-6. Blood (1992) 2.62
Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol (2001) 2.60
TLR6: A novel member of an expanding toll-like receptor family. Gene (1999) 2.55
A member of the C/EBP family, NF-IL6 beta, forms a heterodimer and transcriptionally synergizes with NF-IL6. Proc Natl Acad Sci U S A (1992) 2.55
Ectopic expression of CHOP (GADD153) induces apoptosis in M1 myeloblastic leukemia cells. FEBS Lett (1996) 2.53
Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation. J Biol Chem (2000) 2.50
Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol (2000) 2.41
Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene. Mol Cell Biol (1990) 2.41
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med (2001) 2.37
Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol (2001) 2.36
TLR engagement prevents transplantation tolerance. Am J Transplant (2006) 2.36
IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A (1999) 2.35
Nonmuscle myosin II-B is required for normal development of the mouse heart. Proc Natl Acad Sci U S A (1997) 2.35
Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process. Lancet (1990) 2.35
Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg (1999) 2.33
The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med (1999) 2.32
Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol (2001) 2.29
Role for mitochondrial oxidants as regulators of cellular metabolism. Mol Cell Biol (2000) 2.22
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 2.16
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol (2009) 2.14
NF-IL6, a member of the C/EBP family, regulates E1A-responsive promoters in the absence of E1A. J Virol (1992) 2.10
Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest (1997) 2.10
Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun (2000) 2.10
Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol (2000) 2.09